About this item:

394 Views | 586 Downloads

Author Notes:

E-mail: gretchen.neigh@emory.edu

Conceived and designed the experiments: GNN CLN. Performed the experiments: CLN CSH SAM ERG. Analyzed the data: CLN CSH SAM ERG. Contributed reagents/materials/analysis tools: JSO. Contributed to the writing of the manuscript: CLN GNN.

The authors would also like to thank Sean D. Kelly and Leah Chisholm for their assistance with this work.

The authors have declared that no competing interests exist.

Subjects:

Research Funding:

The authors would like to acknowledge the financial support of The Department of Physiology, Emory University, Atlanta, GA. Additionally, this research was supported by the Creative and Novel Ideas in HIV Research Program (CNIHR) through a supplement to the University of Alabama at Birmingham (UAB) Center For AIDS Research funding (P30 AI027767-24).

This funding was made possible by collaborative efforts of the Office of AIDS Research, the National Institutes of Allergies and Infectious Diseases, and the International AIDS Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Keywords:

  • Science & Technology
  • Multidisciplinary Sciences
  • Science & Technology - Other Topics
  • MAJOR DEPRESSION
  • HIPPOCAMPAL NEUROGENESIS
  • ANTIDEPRESSANT TREATMENT
  • MODEL
  • ADHERENCE
  • CYTOKINES
  • BRAIN
  • DYSFUNCTION
  • SYMPTOMS
  • AIDS

Meloxicam Blocks Neuroinflammation, but Not Depressive-Like Behaviors, in HIV-1 Transgenic Female Rats

Tools:

Journal Title:

PLoS ONE

Volume:

Volume 9, Number 10

Publisher:

, Pages e108399-e108399

Type of Work:

Article | Final Publisher PDF

Abstract:

Adolescents living with human immunodeficiency virus (HIV) comprise approximately 12% of the HIV-positive population worldwide. HIV-positive adolescents experience a higher rate of clinical depression, a greater risk of sexual and drug abuse behaviors, and a decreased adherence to highly active antiretroviral therapies (HAART). Using adolescent HIV-1 transgenic rats (HIV-1 tg) that display related immune response alterations and pathologies, this study tested the hypothesis that developmental expression of HIV-1-related proteins induces a depressive-like phenotype that parallels a decrease in hippocampal cell proliferation and an increase in pro-inflammatory cytokine expression in the hippocampus. Consistent with this hypothesis, adolescent HIV-1 tg rats demonstrated a depressive-like behavioral phenotype, had decreased levels of cell proliferation, and exhibited elevated expression of monocyte chemotactic protein-1 (Mcp-1) in the hippocampus relative to controls. Subsequently, we tested the ability of meloxicam, a selective COX-2 inhibitor, to attenuate behavioral deficits via inflammatory mechanisms. Daily meloxicam treatments did not alter the behavioral profile despite effectively reducing hippocampal inflammatory gene expression. Together, these data support a biological basis for the co-morbid manifestation of depression in HIV-positive patients as early as in adolescence and suggest that modifications in behavior manifest independent of inflammatory activity in the hippocampus.

Copyright information:

© 2014 Nemeth et al.

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits making multiple copies, distribution of derivative works, distribution, public display, and publicly performance, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact.

Creative Commons License

Export to EndNote